Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.

Newsfile May 12, 2021

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DOX, FGEN and GOEV

GlobeNewswire May 11, 2021

FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders

Newsfile May 11, 2021

FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Shareholders of Securities Fraud Class Action Lawsuit

GlobeNewswire May 11, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

Newsfile May 11, 2021

FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

GlobeNewswire May 11, 2021

CLASS ACTION UPDATE for ACAD, FGEN, RMO: Hagens Berman Updates Investors on Securities Class Actions, Advises Investors with Losses to Contact the Firm

ACCESSWIRE IA May 11, 2021

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

PR Newswire May 11, 2021

FGEN, CAN & RMO Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

ACCESSWIRE IA May 11, 2021

FIBROGEN INVESTORS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

ACCESSWIRE IA May 11, 2021

HAGENS BERMAN Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel

PR Newswire May 11, 2021

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire May 10, 2021

ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages FibroGen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FGEN

PR Newswire May 10, 2021

FibroGen Reports First Quarter 2021 Financial Results

GlobeNewswire May 10, 2021

FGEN INVESTORS WHO LOST MONEY; HAGENS BERMAN, National Trial Attorneys, Alerts FibroGen (FGEN) Investors to Securities Class Action, Encourages Investors with Losses to Contact the Firm Now

Newsfile May 10, 2021

Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for FibroGen, Inc. Investors - Expanded Class Period

PR Newswire May 10, 2021

SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Expanded Class Period

ACCESSWIRE IA May 8, 2021

FIBROGEN INVESTOR ALERT: Class Action Lawsuit Filed

Newsfile May 8, 2021

FibroGen Deadline Alert

Newsfile May 8, 2021

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire May 7, 2021